dipyridamole has been researched along with Peritonitis in 4 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Peritonitis: INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study suggests that dipyridamole may have therapeutic potential in treating peritoneal fibrosis." | 7.71 | Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo. ( Fang, CC; Hsieh, BS; Hung, KY; Lee, PH; Shyu, RS; Tsai, CC; Tsai, TJ, 2001) |
| "This study suggests that dipyridamole may have therapeutic potential in treating peritoneal fibrosis." | 3.71 | Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo. ( Fang, CC; Hsieh, BS; Hung, KY; Lee, PH; Shyu, RS; Tsai, CC; Tsai, TJ, 2001) |
| "Chemical peritonitis was the dose-limiting toxicity." | 1.28 | Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole. ( Balis, FM; Cleary, SM; Goel, R; Horton, C; Howell, SB; Kirmani, S; Zimm, S, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caltik, A | 1 |
| Demircin, G | 1 |
| Bülbül, M | 1 |
| Erdogan, O | 1 |
| Akyüz, SG | 1 |
| Arda, N | 1 |
| Umgelter, A | 1 |
| Hung, KY | 1 |
| Shyu, RS | 1 |
| Fang, CC | 1 |
| Tsai, CC | 1 |
| Lee, PH | 1 |
| Tsai, TJ | 1 |
| Hsieh, BS | 1 |
| Goel, R | 1 |
| Cleary, SM | 1 |
| Horton, C | 1 |
| Balis, FM | 1 |
| Zimm, S | 1 |
| Kirmani, S | 1 |
| Howell, SB | 1 |
1 review available for dipyridamole and Peritonitis
| Article | Year |
|---|---|
[Approach to the patient with zirrhotic ascites--no diagnosis without a tap].
Topics: Aminoglycosides; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; | 2010 |
3 other studies available for dipyridamole and Peritonitis
| Article | Year |
|---|---|
An unusual case of ANA negative systemic lupus erythematosus presented with vasculitis, long-standing serositis and full-house nephropathy.
Topics: Administration, Oral; Adolescent; Antibodies, Antinuclear; Azathioprine; Cyclophosphamide; Dipyridam | 2013 |
Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo.
Topics: Animals; Cell Adhesion; Cell Division; Cells, Cultured; Collagen; Cyclic AMP; Dipyridamole; Disease | 2001 |
Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Dipyridamole; Dr | 1989 |